Claimbc69c5215b42b13c6ef856e2a68b6f816458fe2d74d954df3a9e975b665c5e48·My Arguments

A 2025 systematic review and meta-analysis of randomized controlled trials found GLP-1RA use was not associated with significant changes in risk for thyroid, pancreatic, breast, or kidney cancer, with consistent results across subgroups.

Evidence (1)

GLP-1 receptor agonists show little effect on obesity-related cancer risk
Meta-analysis of RCTs showed no significant association between GLP-1RA therapy and thyroid, pancreatic, breast, or kidney cancer risk.
https://www.2minutemedicine.com/glp-1-receptor-agonists-show-little-effect-on-obesity-related-cancer-risk/

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/bc69c5215b42b13c6ef856e2a68b6f816458fe2d74d954df3a9e975b665c5e48"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.